New AMRC White Paper Confirms: Multisite Research Corporations Raise the Bar for Clinical Trial Quality
October 14, 2025
Get in touch to experience the advantage of working with Paradigm Clinical Research, a multisite research corporation.
SAN DIEGO, Calif. — As a founding member of the Association of Multisite Research Corporations (AMRC), Paradigm Clinical Research is proud to support this industry-wide effort to redefine what “quality” truly means in today’s clinical research environment.
AMRC released a white paper that reinforces what we see across our own purpose-built research sites:
Multisite Clinical Research Corporations (MCRCs) consistently deliver:
- Faster study start-up through standardized processes and centralized operational expertise
- Stronger consistency in performance, documentation, and protocol execution
- Higher workforce retention, supporting more experienced, stable site teams
- Expanded access to clinical research in communities that have historically been underserved
These findings underscore what many of you experience firsthand. With unified systems, dedicated research infrastructure, and scalable operational models, sites can deliver higher-quality execution without compromising patient care.
It is time to close the perception gap move towards a clearer, data-driven understanding of quality.
Read White Paper: The MCRC Advantage: Making the Case for Consolidation and Consistency in Clinical Trials
About Paradigm Clinical Research
Paradigm Clinical Research is a long-standing, multi-location, multispecialty clinical research site business with purpose-built research sites in California, Colorado and Idaho. The company operates wholly owned sites that support Phase I-IV clinical trials and provides sponsors with access to diverse, often underrepresented patient populations and investigators. Paradigm’s mission is to enrich lives by offering opportunities to advance the human condition through participation in brilliantly conducted clinical trials.